<DOC>
	<DOCNO>NCT00571337</DOCNO>
	<brief_summary>1 Project summary 1.1 Rational . Accent 1 study demonstrate superiority Infliximab placebo systematic treatment strategy Crohn 's disease every 8 week one year . However optimal strategy beyond one year treatment establish . Particularly , need carry systematic treatment infliximab patient demonstrate . 1.2 Primary objective . Determine factor associate low risk clinical relapse stop infliximab CD patient remission ( CDAI &lt; 150 ) regularly treat infliximab least one year . 1.3 Main objective main judgement criterion . Determine predictive factor relapse within one year stop infliximab . Main judgement criterion clinical relapse stop infliximab . Clinical relapse define either CDAI &gt; 250 CDAI 150 250 CDAI confirm two consecutive week increase least 70 point baseline two consecutive measure . 1.4 Secondary objective judgement criterion . Determine time to-relapse Determine predictive factor short-term relapse ( &lt; 2 month ) stop infliximab . Determine response infliximab retreatment patient . Determine tolerance infliximab retreatment patient . Determine predictive factor absence response retreatment . Determine predictive factor infliximab retreatment intolerance . Determine sustain response retreat patient . 1.5 Type study Open-label prospective study stop regular treatment . Inclusion period : minimum one year , possibly prolong reach 100 patient . Patients follow every two month least 18 month stop infliximab . 1.6 Justification number patient Number patient include least 100 . This recruitment reach within one year . This number allow disclose predictive factor associate relative risk least 2 factor equilibrate ( 50 % risk patient ) 3 factor disequilibrated ( 90 % risk patient ) .</brief_summary>
	<brief_title>Stop Infliximab Patients With Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Inclusion criterion : Crohn 's disease . Age &gt; 18 year . Patient write informed consent . Patient treat infliximab confirm Crohn 's disease active intestinal lesion . Patient treat infliximab least 1 year , associate immunosuppressor least one year , maximum interval 2 infliximab infusion 3 month . Patient continuous remission without steroid least 6 month , except IV steroid infusion reaction prophylaxis . CDAI &lt; 150 . Contraception study . Exclusion criterion : Patient experience severe acute infusion reaction infliximab , define anaphylacto√Ød reaction ( drop blood pressure , bronchospasm , dyspnea ) require arrest infliximab infusion . Patient experience severe delay infusion reaction infliximab , define fever , arthralgia , myalgia , require steroid treatment . Patient dominant perianal disease absence active intestinal disease time infliximab induction . Patient active perianal disease time inclusion . Patient stoma . Patient debilitate extraintestinal manifestation time inclusion . Non cooperate subject . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Stop infliximab .</keyword>
</DOC>